Clinical Trials Sponsored by Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company

Total 165 results

Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo...

Completed

Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy

Essential Hypertension

Korea, Republic of
Daiichi Sankyo
Daiichi Sankyo Korea Co., Ltd.

Active, not recruiting

An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia

Dyslipidemia

Korea, Republic of
Daiichi Sankyo, Inc.
Daiichi Sankyo Korea Co., Ltd.

Recruiting

A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation

Atrial Fibrillation

Korea, Republic of
Daiichi Sankyo, Inc.
Daiichi Sankyo Korea Co., Ltd.

Completed

An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes

Dyslipidemia Associated With Type II Diabetes Mellitus

Korea, Republic of
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company

Completed

Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)

Acute Coronary Syndrome (ACS)

Taiwan
Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company

Completed

Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation

Atrial Fibrillation

United Kingdom
Daiichi Sankyo (Thailand) Ltd., a Daiichi Sankyo...

Completed

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)

Atrial Fibrillation

Thailand
Daiichi Sankyo Co., Ltd.

Recruiting

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Solid Tumor | Metastatic Solid Tumor | Advanced Cancer

Japan, United States, Canada
Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT (PLX3397)

Tenosynovial Giant Cell Tumor

Taiwan, China
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

HER2-positive Advanced Gastric Cancer | HER2-positive Gastroesophageal Junction Adenocarcinoma

Austria, Belgium, Germany, Italy
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo

Active, not recruiting

DS-3201b in Participants With Lymphomas

Lymphoma, Malignant | Non-hodgkin Lymphoma

United States, Japan
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo

Active, not recruiting

A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma

Melanoma

Korea, Republic of, China
Daiichi Sankyo
Daiichi Sankyo Co., Ltd.

Active, not recruiting

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

United States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
Daiichi Sankyo Co., Ltd.

Active, not recruiting

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

Adult T-cell Leukemia/Lymphoma

Japan
Daiichi Sankyo Hong Kong Ltd., a Daiichi Sankyo...

Completed

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)

Atrial Fibrillation

Hong Kong
Daiichi Sankyo Turkey, a Daiichi Sankyo Company
Daiichi Sankyo, Inc.

Completed

Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey (ETAF-TR)

Atrial Fibrillation

Turkey
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

DESTINY Breast Respond HER2-low Europe

Metastatic Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast Cancer

Austria, Belgium, Italy, Spain, France, Switzerland, Denmark, Norway, Sweden
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events (SANTORINI)

Cardiovascular Diseases | Dyslipidemia | Hypercholesterolemia | Atherosclerotic Cardiovascular Disease

Finland, Netherlands, Spain, Belgium, Sweden, Austria, United Kingdom, Switzerland, Denmark, France, Germany, Portugal, Italy, Ireland
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
AstraZeneca

Completed

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Neoplasm, Breast | Adenocarcinoma, Gastric

Taiwan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Withdrawn

Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia (MILOS-Spain)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Isolated Systolic Hypertension in the Elderly and Very Elderly

Isolated Systolic Hypertension

Germany
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

Belgium, Germany, Netherlands, Slovakia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 (OLMEBNP)

Chronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level

Germany, France, Netherlands
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Daiichi Sankyo Germany

Completed

SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®

Hypercholesterolemia | Mixed Dyslipidemia

Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia (MILOS)

Hypercholesterolemia | Mixed Dyslipidemia

Austria, United Kingdom, Italy, Germany, Belgium
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe (ETNA-VTE)

Venous Thromboembolism

Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ENTRUST-AF-PCI)

Atrial Fibrillation

Italy, Netherlands, Spain, Korea, Republic of, Portugal, Hungary, Serbia, United Kingdom, Germany, Belgium, Taiwan, Austria, Switzerland, France, Ukraine, Lithuania, Poland, Romania
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation (ELIMINATE-AF)

Atrial Fibrillation

Spain, Belgium, Korea, Republic of, United Kingdom, Germany, Italy, Taiwan, Hungary, Czechia, Canada, Poland
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

France, Poland, Ukraine, Germany, Spain, Bulgaria, Czechia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

The Confirmatory Olmesartan Plaque Regression Study (CONFIRM)

Essential Hypertension | Carotid Plaque

Italy
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection (ArtStiff)

Hypertension | Metabolic Syndrome

Italy, Belgium, Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure

Hypertension

Spain
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome (VAMOS)

Hypertension | Metabolic Syndrome

Germany
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly

Essential Hypertension

Germany
AstraZeneca
Daiichi Sankyo Co., Ltd.; Daiichi Sankyo Company, Limited

Active, not recruiting

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (DB-08)

Metastatic Breast Cancer

Belgium, United States, Taiwan, Korea, Republic of, Brazil, Russian Federation, Canada, Australia, France, Mexico
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Breast Cancer

China, United States, Spain, Hungary, Israel, Korea, Republic of, Taiwan, Belgium, Austria, Russian Federation, Switzerland, Portugal, France, Canada, Italy, United Kingdom, Greece, Japan, Germany, Sweden
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Breast Cancer

United States, Spain, Israel, Italy, Korea, Republic of, Belgium, Australia, Czechia, Japan, Brazil, France, United Kingdom, Turkey, Greece, Germany
Daiichi Sankyo Co., Ltd.

Completed

Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia

Gastric Cancer

Korea, Republic of, Hong Kong, Taiwan, China
Daiichi Sankyo Co., Ltd.

Completed

Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects

Covid19

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

China
Daiichi Sankyo Co., Ltd.

Completed

A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants

Healthy Subjects | Pharmacokinetics | Drug-drug Interaction | Quizartinib

United States
Daiichi Sankyo Co., Ltd.

Completed

Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

Advanced Solid Malignant Tumors

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects

Respiratory Syncytial Virus Infections

Japan
Daiichi Sankyo Co., Ltd.

Terminated

Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis

Atopic Dermatitis

Japan
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo, Inc.

Completed

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Leukemia, Myeloid, Acute

Japan
Daiichi Sankyo Co., Ltd.

Completed

Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors

Solid Tumors

Japan
Daiichi Sankyo Co., Ltd.

Completed

Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment

Non-valvular Atrial Fibrillation

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery

Venous Thromboembolism

Japan
Daiichi Sankyo Co., Ltd.

Completed

DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation

Stroke | Atrial Fibrillation

Taiwan, Korea, Republic of, Singapore, China
Daiichi Sankyo Co., Ltd.

Completed

A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty

Deep Vein Thrombosis | Venous Thromboembolism | Total Knee Arthroplasty

Japan

Clinical Trials Sponsored by Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations